Novel pharmacotherapeutic treatments for cocaine addiction.
about
Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future researchThe role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.Associations of the 5-hydroxytryptamine (serotonin) receptor 1B gene (HTR1B) with alcohol, cocaine, and heroin abuse.The future potential for cocaine vaccines.A human recombinant monoclonal antibody to cocaine: Preparation, characterization and behavioral studies.Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.Measuring Outcome in the Treatment of Cocaine Dependence.Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users.S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: a microdialysis study.Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.Emerging role for corticotropin releasing factor signaling in the bed nucleus of the stria terminalis at the intersection of stress and reward.Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.Rhodiola rosea Impairs Acquisition and Expression of Conditioned Place Preference Induced by Cocaine.Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.Protein kinase D1-dependent phosphorylation of dopamine D1 receptor regulates cocaine-induced behavioral responses.Medications for substance use disorders.Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.Systematic review of N-acetylcysteine in the treatment of addictions.Substance abuse/dependence treatment: a European perspective.Molecular basis of alcoholism.Norepinephrine regulates cocaine-primed reinstatement via α1-adrenergic receptors in the medial prefrontal cortex.Epigenetics: a link between addiction and social environment.Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study.Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats.Drug use among HIV+ adults aged 50 and older: findings from the GOLD II study.Working towards a new psychiatry - neuroscience, technology and the DSM-5.Knockout of p11 attenuates the acquisition and reinstatement of cocaine conditioned place preference in male but not in female mice.Anxiety status affects nicotine- and baclofen-induced locomotor activity, anxiety, and single-trial conditioned place preference in male adolescent rats.Cocaine Addiction Treatment and Home Remedies: Use of the Scopolamine Transdermal Patch.Bis(mandelato)borate: an effective, inexpensive spiroborate anion for chiral resolution.
P2860
Q22241485-9582F143-B0C5-4537-BCEE-C1D6951DBA7AQ33598487-98A467C0-7767-4693-8AF6-C84B43E13ACBQ33798678-EAC0B5A1-AA69-4A06-8714-27ED4DA34BB8Q33874368-F039D78B-721E-4DD1-AF5E-AE4F641C443FQ34132804-E0C031D9-7050-497D-A3D6-795799A3F433Q34288266-6F4D1879-F863-4153-A4F2-101DC4A73C13Q35468865-8B8D9B71-B461-4F54-97E3-1D57077A6F6AQ36041815-B925A4CF-D352-4B37-8978-BEAE26E26121Q36177517-3ABEDE94-C7C4-4E76-BA4A-673CA1252CDBQ36243255-89BC66F1-100C-4A2E-BEC6-FD2FEE0DA40EQ36852570-55695821-17E1-4FA5-A0A5-45F3BBA4EA4AQ36881952-FE8E9822-3B77-4F5A-9596-40A8759DA924Q37062538-C3031B17-9092-4A5F-9604-D7925A19C6BBQ37172714-C4E24FB4-2F9D-407E-9334-1F6EA48FDA97Q37224633-ACDFAE23-3763-471E-8E33-E818CF040E00Q37282486-2ED57054-CE7F-423F-B373-8ABD415F647DQ37642472-09E8B983-7370-485C-9619-D436D9B5DD60Q38111473-65FBAFC3-D6F8-41DB-8C95-32F316540182Q38133770-B1D42A02-ED05-433E-B124-849CAF7B4DD8Q38199954-D04CF652-DCD4-4FA7-A6AF-2761AB868B4CQ38207160-AE759F39-5F17-4A4D-ADC7-222BAB2564A7Q38259368-FDEF242A-1961-4EDF-84BD-824E2B383A1EQ38845514-CEDAF375-B583-4249-B136-1030E8151CC0Q39159282-E1648DD5-D1F1-4506-B5EB-BE79775B417EQ39519649-2985953B-4A78-470F-B9B7-F63E56F90363Q39642220-C93405F2-73C6-4730-B191-F7F9F3BBAF6DQ39655812-681A1372-8613-4AAB-99B8-4A0BA2B6B107Q40688048-F1AC4222-4689-47D3-A302-152E9FF51C02Q42694230-DF6CB7EB-BEBA-4CA2-A10F-C25CEE00D1E6Q47576276-D7FBE1D1-7046-44FC-B98E-48505FEA9AD1Q47890802-41D74A3B-8641-4731-BEED-9A59B3BBD653Q52303021-F7D6A24C-81AE-4BB7-9463-5E888B418CD5Q53535314-49A69C63-70B3-4513-9A8D-C8746730A37B
P2860
Novel pharmacotherapeutic treatments for cocaine addiction.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Novel pharmacotherapeutic treatments for cocaine addiction.
@ast
Novel pharmacotherapeutic treatments for cocaine addiction.
@en
Novel pharmacotherapeutic treatments for cocaine addiction.
@nl
type
label
Novel pharmacotherapeutic treatments for cocaine addiction.
@ast
Novel pharmacotherapeutic treatments for cocaine addiction.
@en
Novel pharmacotherapeutic treatments for cocaine addiction.
@nl
prefLabel
Novel pharmacotherapeutic treatments for cocaine addiction.
@ast
Novel pharmacotherapeutic treatments for cocaine addiction.
@en
Novel pharmacotherapeutic treatments for cocaine addiction.
@nl
P2860
P356
P1433
P1476
Novel pharmacotherapeutic treatments for cocaine addiction.
@en
P2093
Daryl Shorter
Thomas R Kosten
P2860
P2888
P356
10.1186/1741-7015-9-119
P407
P5008
P577
2011-11-03T00:00:00Z
P5875
P6179
1022411486